

## Contents

Contributors *x*  
Preface *xix*  
Acknowledgments *xxiii*

### Part I Introduction 1

- 1 What Is Pharmacoepidemiology? 3  
*Brian L. Strom*
- 2 Basic Principles of Clinical Pharmacology Relevant to Pharmacoepidemiologic Studies 27  
*Jeffrey S. Barrett*
- 3 Basic Principles of Clinical Epidemiology Relevant to Pharmacoepidemiologic Studies 44  
*Brian L. Strom*
- 4 Sample Size Considerations for Pharmacoepidemiologic Studies 60  
*Brian L. Strom*
- 5 When Should One Perform Pharmacoepidemiologic Studies? 71  
*Brian L. Strom*

### Part II The Role of Pharmacoepidemiology in Different Sectors 81

- 6 The Role of Pharmacoepidemiology in the Healthcare System and Academia 83  
*Joshua J. Gagne and Jerry Avorn*
- 7 The Role of Pharmacoepidemiology in Industry 98  
*Nicolle M. Gatto, Rachel E. Sobel, Jamie Geier, Jingping Mo, Andrew Bate, and Robert F. Reynolds*

**8 The Role of Pharmacoepidemiology in Regulatory Agencies 126**

*Gerald J. Dal Pan, June Raine, and Shinobu Uzu*

**9 Pharmacoepidemiology and the Law 140**

*Aaron S. Kesselheim and Kerstin N. Vokinger*

**Part III Sources of Data for Pharmacoepidemiology Research 165**

**Part IIIa Spontaneous Reporting 167**

**10 Postmarketing Spontaneous Pharmacovigilance Reporting Systems 169**

*Gerald J. Dal Pan, Marie Lindquist, and Kate Gelperin*

**Part IIIb Electronic Data Systems 203**

**11 Overview of Electronic Databases in Pharmacoepidemiology 205**

*Brian L. Strom*

**12 Encounter Databases 211**

*Tobias Gerhard, Yola Moride, Anton Pottegård, and Nicole Pratt*

**13 Electronic Health Record Databases 241**

*Daniel B. Horton, Harshvinder Bhullar, Lucy Carty, Francesca Cunningham, Alexis Ogdie, Janet Sultana, and Gianluca Trifirò*

**14 Inpatient Databases 290**

*James A. Feinstein, Peter K. Lindenauer, Chris Feudtner, and Brian T. Fisher*

**Part IIIc Studies Involving *Ad Hoc* Data Collection 305**

**15 Event Monitoring in the UK 307**

*Vicki Osborne and Saad A.W. Shakir*

**16 Primary Data Collection for Pharmacoepidemiology 342**

*Nancy A. Dreyer, Ana Filipa Macedo, and Priscilla Velentgas*

**Part IIId Choosing a Data Source 355**

**17 Choosing among the Available Data Sources for Pharmacoepidemiology Research 357**

*Brian L. Strom*

## Part IV Selected Applications of Pharmacoepidemiology 373

- 18 **Studies of Drug Utilization** 375  
*Björn Wettermark, Vera Vlahović-Palčevski, David Lee, and Ulf Bergman*
- 19 **Evaluating and Improving Physician Prescribing** 411  
*Christine Y. Lu, the late Sumit R. Majumdar, Helene Lipton, and Stephen B. Soumerai*
- 20 **Pharmacoepidemiologic Studies of Vaccine Safety** 437  
*Robert T. Chen, Jason M. Glanz, and Tom T. Shimabukuro*
- 21 **Epidemiologic Studies of Medical Devices: Methodologic Considerations for Implantable Devices** 496  
*Danica Marinac-Dabic, Sharon-Lise Normand, Art Sedrakyan, and Thomas P. Gross*
- 22 **Research on the Effects of Medications in Pregnancy and in Children** 524  
*Daniel B. Horton, Sonia Hernandez-Diaz, Tamar Lasky, and Krista F. Huybrechts*
- 23 **Study of Biologics and Biosimilars** 561  
*Jeffrey R. Curtis and James D. Lewis*
- 24 **Risk Management** 581  
*Claudia Manzo, Emil Cochino, Lubna Merchant, and Giampiero Mazzaglia*
- 25 **Distributed Networks of Databases Analyzed Using Common Protocols and/or Common Data Models** 617  
*Sengwee Toh, Nicole Pratt, Olaf Klungel, Joshua J. Gagne, and Robert W. Platt*
- 26 **Comparative Effectiveness Research** 639  
*Soko Setoguchi and Ian Chi Kei Wong*
- 27 **Data Mining and Other Informatics Approaches to Pharmacoepidemiology** 675  
*Andrew Bate, Gianluca Trifirò, Paul Avillach, and Stephen J.W. Evans*
- 28 **Pharmacoepidemiologic Research on Drugs of Abuse** 701  
*Jana McAninch, Alex Secora, Cynthia Kornegay, and Judy Staffa*

## Part V Selected Special Methodologic Issues in Pharmacoepidemiology 723

- 29 **Assessing Causation from Case Reports** 725  
*Judith K. Jones, Bernard Bégaud, and Elyse Kingery*
- 30 **Molecular Pharmacoepidemiology** 746  
*Christine Y. Lu and Stephen E. Kimmel*

- 31 Bioethical Issues in Pharmacoepidemiologic Research 772**  
*Laura E. Bothwell, Annika Richterich, and Jeremy Greene*
- 32 The Use of Randomized Controlled Trials in Pharmacoepidemiology 792**  
*Robert F. Reynolds, Samuel M. Lesko, Nicolle M. Gatto, Tjeerd P. van Staa, and Allen A. Mitchell*
- 33 The Use of Pharmacoepidemiology to Study Beneficial Drug Effects 813**  
*Brian L. Strom and the late Kenneth L. Melmon*
- 34 Pharmacoeconomics: The Economics of Pharmaceuticals 837**  
*Kevin A. Schulman*
- 35 Benefit–Risk Assessments of Medical Treatments 867**  
*Bennett Levitan, Rachael DiSantostefano, and Scott Evans*
- 36 The Use of Metaanalysis in Pharmacoepidemiology 897**  
*Jesse A. Berlin, Brenda J. Crowe, H. Amy Xia, and Stephen J.W. Evans*
- 37 Validity of Drug and Diagnosis Data in Pharmacoepidemiology 948**  
*Mary Elizabeth Ritchey, Suzanne L. West, and George Maldonado*
- 38 Studies of Medication Adherence 991**  
*Julie Lauffenburger, Trisha Acri, and Robert Gross*
- 39 Risk Evaluation and Communication 1010**  
*Susan J. Blalock, Rebecca Dickinson, and Peter Knapp*
- 40 Methods for Studying the Health Effects of Drug–Drug Interactions 1030**  
*Sean Hennessy, Charles E. Leonard, Joshua J. Gagne, James H. Flory, Colleen M. Brensinger, and Warren B. Bilker*
- 41 The Pharmacoepidemiology of Medication Errors 1046**  
*Hanna M. Seidling and David W. Bates*
- 42 Patient Engagement and Patient-Reported Outcomes 1061**  
*Esi M. Morgan*
- 43 Advanced Approaches to Controlling Confounding in Pharmacoepidemiologic Studies 1078**  
*Sebastian Schneeweiss and Samy Suissa*

**Part VI Conclusion 1109**

- 44 The Future of Pharmacoepidemiology 1111**  
*Brian L. Strom, Stephen E. Kimmel, and Sean Hennessy*

**Appendix A Sample Size Tables 1123**

**Appendix B Glossary 1141**

**Index 1155**